Letters by company
Hims & Hers Health, Inc.
4 letters discussing HIMS. Everything written about it on this site is on its ticker page.
- Cedar Grove Capital Management Q3’2026 Cedar Grove increased gross leverage and added Zedcor, OneSpaWorld and Auxly while closing several special-situation and biotech holdings. The portfolio argues that Evolv Technologies and The RealReal retain improving operating fundamentals despite rate-driven valuation pressure, with recurring revenue and marketplace efficiency as the central theses. Q3 2026 EVLV $811MABVX $8BAXON $26B
- Cedar Grove Capital Management Q2’2026 Cedar Grove broadened the portfolio, added event-driven opportunities and increased shorts as AI-led market leadership favored momentum over valuation-sensitive stock selection. It exited SANUWAVE after reimbursement disruption cut device guidance, reduced KITS after its bitcoin ETF treasury decision, and added telehealth, neurology and grid-modernization positions. Q2'26 ABVX $8BCLPT $272MHIMS $4.9B
- Cedar Grove Capital Management Q1 2026 Cedar Grove Capital Management deployed capital into small and microcap healthcare and consumer-discretionary names it viewed as mispriced amid the SaaS selloff. It exited the failed LENSAR merger-arbitrage position, sharply reduced and then sold WW International after weakening subscriber trends and a CEO departure, while retaining core positions in KITS, The RealReal, Evolv and Sanuwave. Q1 2026 ABVX $8BEVLV $811MHIMS $4.9B
- Unconventional Value Year End 2025 Letter Planet remains the largest holding after a partial sale funded additions to Pagaya, Remitly, Thryv and Hims and Hers, as the manager reassesses valuation while backing its daily-scan data platform. Thryv is framed as a cash-flow mispricing tied to SaaS conversion. Remitly is backed for digital remittance share gains, scale economics and adjacent financial services. Year End 2025 PL $5.2BRELY $4.9BTHRY $43M
